Skip to Content

Join the 'Follicular Lymphoma' group to help and get support from people like you.

Follicular Lymphoma News

FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma

Posted 25 Sep 2018 by Drugs.com

BOSTON--(BUSINESS WIRE)--Sep. 24, 2018-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has approved Copiktra, an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual ...

Kymriah (tisagenlecleucel) Receives Second FDA Approval to Treat Appropriate Patients with Large B-Cell Lymphoma

Posted 4 Jun 2018 by Drugs.com

Basel, May 1, 2018 - Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell ...

Get Active, Beat Lymphoma?

Posted 12 Dec 2017 by Drugs.com

TUESDAY, Dec. 12, 2017 – Physical activity appears to help people with lymphoma survive their disease. That finding comes from a new study by Mayo Clinic researchers of nearly 4,100 people with lymphoma, a cancer that starts in the white blood cells that normally help fight infection. "As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but ...

FDA Approves Genentech’s Gazyva for Previously Untreated Advanced Follicular Lymphoma

Posted 23 Nov 2017 by Drugs.com

South San Francisco, CA – November 16, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva alone in those who responded, for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV). The ...

Newer Drug May Prolong Lymphoma Remission

Posted 5 Oct 2017 by Drugs.com

WEDNESDAY, Oct. 4, 2017 – A newer drug may beat the standard treatment when it comes to battling the blood cancer follicular lymphoma, a clinical trial suggests. Follicular lymphoma is one type of non-Hodgkin lymphoma, a group of cancers that arise in white blood cells. The new study found that a drug called obinutuzumab (Gazyva) typically kept the cancer under control longer, versus the ...

FDA Approves Aliqopa (copanlisib) for Adults with Relapsed Follicular Lymphoma

Posted 17 Sep 2017 by Drugs.com

September 14, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments,” said Richard Pazdur, M.D., dir ...

Aliqopa Approved for Follicular Lymphoma

Posted 14 Sep 2017 by Drugs.com

THURSDAY, Sept. 14, 2017 – Aliqopa (copanlisib) has been approved by the U.S. Food and Drug Administration to treat adults with relapsed follicular lymphoma who have received at least two prior treatments with certain other drugs. Follicular lymphoma is a slow-growing cancer of the lymph system of the type known as non-Hodgkin lymphoma. More than 72,000 people in the United States are likely to ...

FDA Approves Rituxan Hycela (rituximab and hyaluronidase human) for Subcutaneous Injection in Certain Blood Cancers

Posted 26 Jun 2017 by Drugs.com

South San Francisco, CA – June 22, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory ...

DNA Sequencing May Lead to Personalized Cancer Treatment

Posted 9 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – DNA sequencing may help personalize treatment for people with lymphoma, a new study suggests. By analyzing small bits of DNA in the blood, researchers at Stanford University School of Medicine said they could determine the cancer's subtype. They said they could also identify mutations that might make treatment less effective or worsen a patient's prognosis. The study ...

Immune Therapy Makes Headway Against a Lymphoma

Posted 8 Sep 2016 by Drugs.com

THURSDAY, Sept. 8, 2016 – Genetically engineered immune cells appear capable of eradicating non-Hodgkin lymphoma when coupled with effective chemotherapy, a new early trial finds. In this experimental therapy, white blood cells known as T-cells are removed from the patient's bloodstream. Then they're genetically modified so they can detect and attack cancerous B-cells, another type of white ...

FDA Approves Genentech’s Gazyva (obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma

Posted 29 Feb 2016 by Drugs.com

South San Francisco, CA – February 26, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinutuzumab) plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan (rituximab)-containing regimen, or whose ...

FDA Approves Zydelig (idelalisib) for CLL and Lymphoma

Posted 23 Jul 2014 by Drugs.com

July 23, 2014 – The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed). Used in combination with Rituxan (rituximab), Zydelig is to be used in patients for whom Rituxan alone would be considered ...

Zydelig Approved for Three Types of Blood Cancer

Posted 23 Jul 2014 by Drugs.com

WEDNESDAY, July 23, 2014 – Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL), the FDA said Wednesday in a news release. The approval for the three forms of blood cancer covers instances when the ...

Ask a Question

Further Information

Related Condition Support Groups

B Cell Lymphoma

Related Drug Support Groups

clarithromycin, Rituxan, rituximab, interferon alfa-2b, duvelisib, Rituxan Hycela, Aliqopa, Copiktra, obinutuzumab, view more... idelalisib, hyaluronidase / rituximab, copanlisib, Intron A, Gazyva, Zydelig